What is the role of steroids in infants with biliary atresia after Kasai hepatoportoenterostomy?

Role of Steroids in Babies with Biliary Atresia Post-Kasai Surgery

Current major guidelines do not recommend routine high-dose corticosteroid therapy initiated within 72 hours of Kasai portoenterostomy, though emerging evidence suggests selective, tailored steroid protocols may improve outcomes when applied to specific patient populations.

Guideline Recommendations

The 2014 AASLD/AST/NASPGHAN practice guideline explicitly states that high-dose corticosteroid therapy initiated within 72 hours of hepatoportoenterostomy (Kasai procedure) is NOT recommended 1. This recommendation is based on Level 1-B evidence and represents the current standard of care from major hepatology societies.

The guidelines emphasize that there is no effective medical therapy for children with biliary atresia 2. The focus remains on:

• Early Kasai portoenterostomy (ideally within first 2 months of life)
• Monitoring for transplant need based on bilirubin levels at 3 months post-Kasai
• Prompt referral for liver transplantation when total bilirubin >6 mg/dL at 3 months 1

Evidence from Clinical Trials

The Definitive Negative Trial

The START trial (2014) - the largest and highest quality randomized controlled trial - definitively showed that high-dose steroids (methylprednisolone 4 mg/kg/day IV for 2 weeks, then prednisolone 2 mg/kg/day oral for 2 weeks, followed by 9-week taper) initiated within 72 hours of Kasai surgery did NOT improve outcomes 3:

• No improvement in bile drainage at 6 months: 58.6% steroids vs 48.6% placebo (p=0.43)
• No improvement in transplant-free survival at 24 months: 58.7% vs 59.4% (p=0.99)
• Earlier onset of serious adverse events in steroid group (37.2% vs 19.0% by 30 days post-op, p=0.008)

This trial directly contradicts the routine use of early high-dose steroids.

Earlier Mixed Results

A 2007 randomized trial showed modest early benefit (lower bilirubin at 1 month, particularly in infants <70 days old at surgery) but no difference in transplant rates at 6 or 12 months 4. This suggests any steroid benefit is transient and doesn't affect meaningful long-term outcomes.

Emerging Evidence: Tailored Steroid Protocols

Recent 2026 studies suggest a paradigm shift toward selective steroid use, contradicting the blanket guideline recommendation:

Key Findings from Recent Research

Tailored protocols based on postoperative stool color and inflammation show promise 5, 6:

• Selective steroid use (only for infants with acholic stools post-operatively OR age ≤45 days with acute inflammation on biopsy) improved:
  • 3-month bilirubin clearance: significantly lower levels (0.9 vs 6.5 mg/dL, p=0.036) 6
  • 2-year native liver survival: 72.9% vs 37.5% (p=0.046) 6
  • 6-month jaundice clearance: 61.4% vs 38.6% (OR 2.53, p=0.013) 5

Meta-Analysis Findings (2022)

A systematic review of 11 studies (1,032 patients) demonstrated 7:

• Improved jaundice clearance at 6/12/24 months (RR: 1.35,1.49,1.41 respectively)
• Improved 24-month native liver survival (RR: 1.31, p=0.028)
• No improvement in short-term (6/12-month) survival
• Greatest benefit in infants ≤70 days old at Kasai
• Medium-dose IV followed by oral administration more effective than high-dose protocols

Italian Registry Data (2026)

Large retrospective analysis of 309 infants confirmed postoperative corticosteroid use as strongest predictor of jaundice clearance (OR 2.51, p=0.0027), even more significant than age at surgery 8.

Clinical Algorithm for Steroid Use

DO NOT USE steroids if:

• Routine prophylaxis within 72 hours of Kasai (per guideline recommendation) 1
• Age >70 days at Kasai with good early bile drainage (yellow stools)
• Concerns about infection risk or other contraindications

CONSIDER selective steroid use if:

1. Persistent acholic stools post-operatively (stool color ≤3 on Japanese Tochigi card) 6
2. Age ≤70 days at Kasai (preferably ≤45 days) 5, 7, 4
3. Evidence of acute inflammation on operative liver biopsy 6

Recommended Protocol (when steroids used):

• Moderate-dose prednisolone (NOT high-dose methylprednisolone)
• Start based on postoperative assessment, not immediately post-op
• Duration: 5 weeks with antibiotic prophylaxis 6
• Medium initial dosage appears optimal (specific dosing varies by protocol) 7

Critical Caveats

The evidence conflict is significant: Major guidelines say no steroids, while recent high-quality studies suggest benefit with tailored approaches. This discrepancy exists because:

1. The START trial used non-selective, high-dose, immediate steroids - exactly what newer protocols avoid 3
2. Tailored protocols are selective - treating only high-risk patients with poor early drainage 5, 6
3. Timing and dosing matter - moderate doses started after assessing bile flow differ from prophylactic high-dose regimens

One study showed NO benefit from steroids in their cohort, emphasizing that results may vary by center and protocol 9.

Practical Recommendation

In real-world practice, prioritize early Kasai surgery (before 70 days of age) over steroid therapy. If postoperative bile drainage is poor (persistent acholic stools), consider a trial of moderate-dose prednisolone with antibiotic prophylaxis for 5 weeks, particularly in younger infants. However, recognize this contradicts current guideline recommendations and should be discussed with families as an evolving area of practice.

Most importantly: Focus on close monitoring of total bilirubin at 3 months post-Kasai. If >6 mg/dL, promptly refer for liver transplantation evaluation 1. Steroids should never delay appropriate transplant referral, as transplantation remains the definitive treatment for failed Kasai procedures with excellent outcomes (93% 1-year survival, >85% 5-year survival) 2.